Combining targeted therapy and chemo for advanced liver cancer
Part of Cancer clinical trials.
This study tests a combination of treatments for liver cancer that cannot be removed with surgery. It combines a procedure called TACE, which delivers chemo directly to the tumor, with drugs that boost your immune system and block cancer growth. This might help shrink tumors and slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 68 years old
- Your liver cancer cannot be removed with surgery
- You have at least one tumor that can be measured on a scan
- You are in fairly good health overall (able to do light activity and not bedridden)
- Your liver, kidney, and blood counts are good enough (your doctor will confirm this)
- You are not pregnant or breastfeeding, and do not plan to have children during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. It uses a procedure to block the tumor's blood supply plus two drugs that help the immune system fight the cancer. This may help shrink tumors and slow the disease.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
Hear when a new Unresectable Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.